Severe Malaria
Conditions
Keywords
Rectal artesunate, Artemisinin-based Combination Therapy, Injectable artesunate, Community Health Worker, Health Facility
Brief summary
The goal of this observational study is to assess whether the giving of rectal artesunate and a three day course of an Artemisinin based Combination Therapy (ACT) to children aged 6 months and ≤ 5 years with severe malaria when referral is not feasible is non inferior to giving of injectable artesunate and three day course of an ACT. The three primary objectives are: * To evaluate the 28-day PCR corrected cure rate in children aged 6 months to ≤ 5 years treated with RAS+ACT or RAS+injectable artesunate, assessing whether each treatment achieves the clinically acceptable cure rate of 97% ± 5%. * To evaluate feasibility of provision of rapid treatment of severe malaria with rectal artesunate in children 6 months to ≤ 5 years not able to access a referral health facility, by a community health worker or in health facility where there is no injectable artesunate available. * To evaluate the impact of reinforcing the integrated Community Case Management (iCCM) on access to the formal health care system The study is being done in Nchelenge district in Zambia and Kapolowe district in the Democratic Republic of Congo. It will enrol 1008 children with severe malaria and an equal number of children with simple malaria
Interventions
DRUGTreatment of severe malaria with either RAS + ACT or RAS + injectable artesunate + ACT will each achieve the clinically acceptable cure rate of 97% ± 5% in remote areas
The Community Health Worker will give rectal artesunate (RAS) +artemisinin based combination Therapy (ACT) to children aged 6 months to less than or equal to 5 years who fail to make the referral trip. Those who make the referral trip will receive injectable artesunate and artemisinin based Combination Therapy for three days. Giving of RAS +ACT is unique to this study. Children with non malaria severe disease will also receive amoxicillin from the community health worker before they are referred to the next level of care
Sponsors
Tropical Diseases Research Centre, Zambia
Universiteit Antwerpen
University of Kinshasa
National Institute for Medical Research, Tanzania
Medicines for Malaria Venture
Université de Lubumbashi
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to 5 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for severe malaria * From a village without other research interventions * Children aged from 6 months to ≤5 years that present at the health system and are either; with fever (or history of fever within 2 days) and have a positive mRDT test plus at least one of the following danger signs for malaria (as per standardized national iCCM guidelines): * convulsions * inability to drink, eat, or suck * vomiting all liquids and solids * altered consciousness/coma * lethargy * chest in-drawing Inclusion for uncomplicated malaria * Children aged from 6 months to ≤5 years; with fever (or history of fever within 2 days) with no danger signs for malaria (as per the standardized national Integrated Management of Childhood Illnesses guidelines) with a positive mRDT for Plasmodium falciparum histidine-rich protein. Inclusion for severe non-malaria * From a village without other research interventions * Children aged from 6 months to ≤5 years that present at the health system and are either; with fever (or history of fever within 2 days) and have a negative mRDT test plus at least one of the following danger signs as per standardized national iCCM guidelines: * convulsions * inability to drink, eat, or suck * vomiting all liquids and solids * altered consciousness/coma * lethargy * chest in-drawing * For participants in sentinel sites, a written informed consent will be provided by the patient's parent or guardian to take filter paper blood samples and to participate in interviews (questionnaires and IDI) at enrolment, day 14 and day 28 (to assess malaria recurrence and look for markers of resistance). If the parent or guardian is unable to write, thumb print witnessed consent is permitted. The informed consent shall be administered by the CHWs. Willingness and ability of the patient and the parent or guardian to comply with the treatment policy.
Exclusion criteria
* Use of any investigational or non-registered product or planned use during the study period. * Participation in other studies within 30 days before the current study begins and/or during study participation. * Inability to comprehend and/or unwillingness to follow the study protocol. * For RAS use: if the child has reacted badly to artesunate in the past (in sites where RAS is administered)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time from onset of symptoms to initiating treatment | The time from onset of symptoms to initiating treatment | The time from onset of symptoms to initiating treatment among children 6 months to ≤5 years with severe malaria and/or not able to take oral treatment that seek health care from the CHW or other HF system as primary first contact |
| PCR-corrected cure rate at 28 days from enrollment in patients aged 6 months to ≤5 years. | 28 Days from enrollment | PCR-corrected cure rate at 28 Days from enrollment in patients aged 6 months to ≤5 years in areas where referral for follow-up treatment with injectable artesunate is not feasible, compared to outcomes obtained after full referral is completed |
| Change from baseline proportion of sick children 6 months - ≤5 years at population level that went to the formal health system during the last 6 months including suspected (severe) malaria at month 20 (phase 4). | At month 20 (phase 4) | Two cross section surveys one at month 1 (baseline) and the other at month 20 (phase 4) will be used to obtain the proportion of sick children 6 months to ≤5 years at population level that were either attended by a Community Health Worker, Health post or Health Centre in the last 6 months |
Countries
Democratic Republic of the Congo, Zambia
Outcome results
None listed